Gabapentin and Immunodeficiency common variable - a phase IV clinical study of FDA data

Summary:

Immunodeficiency common variable is reported as a side effect among people who take Gabapentin (gabapentin), especially for people who are female, 60+ old, have been taking the drug for 6 - 12 months also take Xyrem, and have Narcolepsy.

The phase IV clinical study analyzes which people have Immunodeficiency common variable when taking Gabapentin. It is created by eHealthMe based on reports of 313,421 people who have side effects when taking Gabapentin from the FDA, and is updated regularly.

What is Gabapentin?

Gabapentin has active ingredients of gabapentin. It is often used in peripheral neuropathy. eHealthMe is studying from 322,990 Gabapentin users. Check the latest studies of Gabapentin.

What is Immunodeficiency common variable?

Immunodeficiency common variable is found to be associated with 86 drugs and 143 conditions by eHealthMe. Check the latest studies of Immunodeficiency common variable.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

313,421 people reported to have side effects when taking Gabapentin.
Among them, 26 people (0.01%) have Immunodeficiency common variable.

Could Gabapentin cause Immunodeficiency common variable?

Among these 26 people:

How long have people been on Gabapentin when they have Immunodeficiency common variable? *

What is the gender of people who have Immunodeficiency common variable when taking Gabapentin? *

female: 54.17 %
male: 45.83 %

What is the age of people who have Immunodeficiency common variable when taking Gabapentin? *

What are other drugs people take besides Gabapentin? *

What are other side effects people have besides Immunodeficiency common variable? *

Granuloma Skin (a small area of inflammation on skin due to tissue injury): 9 people, 34.62%
Skin Exfoliation (removal of the oldest dead skin cells): 6 people, 23.08%
Skin Mass: 6 people, 23.08%
Peripheral Swelling: 6 people, 23.08%
Fatigue (feeling of tiredness): 5 people, 19.23%
Neuropathy Peripheral (surface nerve damage): 3 people, 11.54%
Infection: 3 people, 11.54%
Weight Decreased: 3 people, 11.54%
Hypogammaglobulinaemia (an abnormally low concentration of gamma globulin in the blood and increased risk of infection): 3 people, 11.54%
Chronic Thyroiditis (long lasting inflammation of thyroid gland): 3 people, 11.54%

What are the existing conditions these people have? *

Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 11 people, 42.31%
Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 9 people, 34.62%
Cataplexy (loss of muscle tone accompanied by full conscious awareness): 8 people, 30.77%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 2 people, 7.69%
Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 2 people, 7.69%
Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 1 person, 3.85%
Burkitt Lymphoma (cancer of the lymphatic system): 1 person, 3.85%

* Approximation only. Some reports may have incomplete information.

Do you take Gabapentin and have Immunodeficiency common variable?

- Check whether Immunodeficiency common variable is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Gabapentin:

Gabapentin (322,990 reports)

Browse all side effects of Gabapentin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Immunodeficiency common variable:

Immunodeficiency common variable (86 drugs)

Browse all the conditions that are associated with Immunodeficiency common variable:

Immunodeficiency common variable (143 conditions)

Related publications that referenced our studies

de Landaluce, L. O., Carbonell, P., Asensio, C., Escoda, N., López, P., & Laporte, J. R. , "Gabapentin and Pregabalin and Risk of Atrial Fibrillation in the Elderly: A Population-Based Cohort Study in an Electronic Prescription Database", Drug safety, 2018 Jan .
Scarff JR, "The Potential for Somnambulism Associated with Gabapentin", The Internet Journal of Psychiatry, 2014 Jan .
de Landaluce, L. O., Carbonell, P., Asensio, C., Escoda, N., López, P., & Laporte, J. R. , "Gabapentin and Pregabalin and Risk of Atrial Fibrillation in the Elderly: A Population-Based Cohort Study in an Electronic Prescription Database", Drug safety, 2018 Jan .
Scarff JR, "The Potential for Somnambulism Associated with Gabapentin", The Internet Journal of Psychiatry, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on gabapentin (the active ingredients of Gabapentin) and Gabapentin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.